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Abstract 
Background: Circulating tumor cells (CTCs) represent one of the most interesting target in improving diagnosis, 
prognosis and treatment. Herein we evaluate the possibility of using an emo-cytometric approach on the evalua-
tion of the heterogeneous population of CTCs to improve personalized metastatic risk assessment. We benchmarked 
ex vivo behavior of distinct subsets of circulating colon tumor cells with correspondent clinical behavior of patients 
from which we isolated CTCs.
Methods: Isolation and CTC expansion were performed by a gradient protocol. In vitro characterization was deter-
mined by flow cytometry, immunofluorescence, western blotting and proteomic profiling. Cell sorter was performed 
with immunomagnetic beads. Confocal microscopy was used to evaluate tissue sections. Kaplan Mayer curves was 
cared for through Medcalc program.
Results: We collected heterogeneous CTCs, derived from the whole blood of seven patients affected by colon 
cancer, expressing CD133posCD45neg (5 ± 1) and (2 ± 1) and CK20posCD45neg of (29 ± 3) (11 ± 1) cells/ml in Dukes D 
and A stage respectively. Proliferation rate of 57 ± 16 %, expression for CXCR4pos of 18 ± 7 % and detectable levels 
of IL-6, IL-8 and SDF-1 cytokines in conditioned culture medium characterized short-time expanded–CTCs (eCTCs). 
ECTCs organized in tumor sphere were CD45negCD133pos while in adhesion were CXCR4posCK20pos. These two subsets 
were separately injected in mice. The first group of xenografts developed superficial lesions within 2 weeks. In the 
second group, in absence of growing tumour, the survival of injected eCTCs was monitored through SDF-1 serum 
levels detection. The detection of human cancer cells expressing CK20, in mice tissues sections, suggested a differ-
ent biological behaviour of injected eCTC-subsets: tumorigenic for the first and disseminating for the second. The 
benchmarking of the experimental data with the clinical course highlights that patients with prevalence of circulating 
cancer stem cells (CD45negCD133pos) have a lower overall survival. Conversely, patients with prevalence of circulating 
differentiated cells (CXCR4posCK20pos) have a low disease-free survival.
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Background
Circulating tumor cells (CTCs) are a highly heteroge-
neous population of circulating progeny derived from 
primary tumor lesion [1]. Their circulation in the blood-
stream has a bidirectional dynamism because CTCs are 
released and attracted by tumor tissue that transiently 
recaptures and releases them through the cytokines pro-
duction [2]. This dynamism guarantees a continuous 
replacement of the CTCs pool in the bloodstream, so the 
characterization of these cells can detail the molecular 
changes occurring in the cancer lesion/s during its evo-
lution. Up to date, the isolation and characterization of 
CTCs through a simple blood test represent an impor-
tant step in monitoring cancer patients. In fact, only 
the analysis of the cancer cells referred by tissue biopsy 
is regarded as appropriate in the diagnostic and prog-
nostic evaluation. But often the tissue biopsy cannot be 
performed for reasons related to poor clinical condition 
or due to critical location of the tumor or for its numer-
ous relapsing lesions. For this reason, the liquid biopsy 
designed for the isolation of cancer cells constitutes a 
potential alternative for clinicians.
For the optimization of both CTCs isolation and their 
in vitro expansion procedures here described, we started 
from the consideration that CTCs release happens in two 
ways, (i) spontaneously—due to high growing tumor pro-
file—and (ii) by active extravasations process—due to the 
acquisition of metastatic phenotype. Taking into account 
the heterotypical composition of the tumor tissue gener-
ating circulating cancer progeny [3, 4] we examined the 
cell populations of peripheral blood samples, without 
preliminary specific selection. The most used and estab-
lished methodology to separate different hematological 
cellular populations within a blood sample, is the den-
sity gradient centrifugation [5]. In this work, by applying 
density gradient we highlighted the presence of CTCs of 
colon cancer in referred density range (working density 
phase). Moreover, considering that the hallmark of can-
cer is the higher proliferation rate, we tested CTCs cellu-
lar growth efficiency in vitro. Expanded-CTCs (e-CTCs) 
become viable for further molecular characterization and 
numerically sufficient for developing human orthotropic 
xenografts. Many studies have shown that the tumor tis-
sue has a hierarchical organization. In particular, cancer 
cell subpopulations are arranged into tumorigenic (can-
cer stem cells compartment) and non-tumorigenic cells 
(cancer differentiated cells compartment). Relative stud-
ies distinguishing CTCs subgroups were reported [6, 7] 
and in particular, high count of CTCs expressing cancer 
stem cell phenotype is considered sign of adverse prog-
nosis [8, 9]. In this study, we tried to distinguish staminal 
and differentiated CTCs in the bloodstream of colon can-
cer patients, to transplant these cells in immunodeficient 
mice for unmasking their biological properties.
Experimental section
Patients
All patients and healthy volunteers enrolled at University 
of Catanzaro (from February 2011) were informed of the 
investigational aspects of this study and provided writ-
ten consent in accordance with local and international 
institutional guidelines [10]. Local ethical committee 
approved the study with the number: 2013.34. Periph-
eral blood samples collected amounted to a volume of 
5  ml for each patient. However, a volume of 15  ml was 
collected from seven patients, five males and two females 
without any type of previous anticancer treatments, to 
develop the xenograph. The average age was 60  years, 
ranging from 34 to 76 years. Two independent patholo-
gists confirmed the histological diagnosis of cancer. Stage 
was determined in agreement with TNM stage (Tumor-
Node-Metastasis, UICC-2009) and Dukes Classification.
Methods
Isolation and expansion (short‑term cultivation)
Ficoll-Paque Plus (GE Healthcare) was used for cancer 
cells separation and the 1.080  ÷  1.090  g/ml gradient 
phase [6, 11] was identified as working density phase. 
The working density phase of CTCs Cytokeratin 20 
(CK20)pos and CD45neg was verified for sensitivity, speci-
ficity and purity, as reported in Additional file 1: Figure 
S1. Moreover, to confirm the specificity of the working 
density phase we performed: (a) a simulation experiment 
(Additional file  1: Figure S2) with a mixture of hema-
tological cells and colon cancer cells (different concen-
tration of GFP-conjugated HCT116 were put in entire 
blood sample and were evaluated through cytometric 
analysis); (b) we compared the working density phase 
with the overlaid one, 1.077–1.080 (g/ml), in which 
monocytes and lymphocytes (mononuclear cell layer) 
are located, for the presence of CK20 and Fibronec-
tin positive cells. The final resolution of the simulation 
Conclusion: On the basis of the heterogeneous composition and despite the low number of CTCs, it was possible to 
distinguish two subgroups of CTCs, suggesting a different clinical outcome. CTC-subsets detailing is useful to better 
define the metastatic–risk personalized score thus improving disease management and reducing patient care cost.
Keywords: Circulating colon tumor differentiated/stem cells, Metastatic-risk stratification
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experiment was estimated of 5.8 cell/ml, as detailed in 
Additional file 1: Figure S2.
After the isolation of the CTCs from the working den-
sity phase, phosphate buffered saline (PBS)-washed 
CTCs were recovered in a culture medium used to pro-
mote cells adhesion [6, 11, 12] and in parallel in a culture 
medium promoting sphere formations, as previously 
reported [7]. Briefly, sphere medium used was D-MEM/
F12- Heparin 0.5  U/ml, EGF 50  ng/ml, FGF 25  ng/ml, 
BSA 1  %, penicillin–streptomycin solution 1  %. 1/3 of 
washed cells was processed for cytometric analysis to 
set up the phenotypes just before the cell seeding. CTCs 
were expanded for 14  days (short-term cultivation). 
The short-term cultivation provided (Fig. 1) amounts of 
CTCs sufficient for cytometry and immunofluorescence 
protocols. Cells were observed with Inverted Confocal 
Microscopy Nikon TE2000 using 408 (blue fluorescence) 
and 543 (red fluorescence) filters, images were digitally 
captured and merged using Adobe Photoshop software 
(v7.0).
Moreover, protein extraction was performed as previ-
ously described [11], and the conditioned medium (aged 
14 days) was analyzed (Proteome Profiler, RD system).
Characterization of eCTCs
For flow cytometry analysis, cells were washed and incu-
bated at 4  °C with primary antibodies. In particular, 
Epcam-FITC and CD133-PE (Miltenyi Biotec), CD45-
APC-H7 (BD), fibronectin (SouthernBiotech) and CK20 
(Abcam) were used. Moreover, secondary antibody 
(Southern Biotech) conjugates with FITC or PE were 
used. All primary antibodies were used at a dilution 
of 1:100 and secondary at 1:1000. Flow cytometry was 
performed with a FACS Canto II (Becton–Dickinson) 
analyzed with Cellquest software. S-phase and DNA con-
tent was carried out as previously described [13].
For CXCR4 MACS-sorting CXCR4-antibody (clone 
12G5; R&D) was used and eCTCs-CXCR4pos were iso-
lated using immunomagnetic CXCR4-microbeads and 
a magnetic cell separation device (Midi-MACS; Milte-
nyi Biotec). Briefly, all cultivated cells were detached by 
trypsinization, collected by centrifugation and washed 
in PBS. eCTCs suspensions were incubated for 30  min 
with phycoerythrin (PE)-conjugated anti-CXCR4 anti-
body, washed, and then incubated for 1  h with anti-PE 
MicroBeads. After washing, cells were separated on LD 
(+) columns for positive and negative selection respec-
tively, according to the manufacturer’s instructions. 
CXCR4-expression of sorted fractions was checked by 
FACS-analysis with the PE-conjugated sorting antibody. 
In addition, total eCTCs, as well as sorted fractions, were 
analyzed by FACS for CK20 and CD133 expression.
SCID xenografts
Severe combined immunodeficiency (SCID) mice (Har-
lan Laboratories) were cared for according to the insti-
tutional guidelines for animal care. The eCTCs were 
subcutaneously injected, without anaesthesia, in the mice 
right flank. 1.5 × 105 tumour cells eCTCs-CXCR4posCK-
20posCD45neg were suspended in 100  μl of matrigel (BD 
Biosciences) and injected in 21 mice. Moreover, eight 
mice were injected with 1.5 ×  105 tumour cells eCTCs-
CXCR4negCK20negCD45neg, four mice with 1  ×  104 
tumour cells eCTCs-CD133posCK20posCD45neg and two 
with matrigel alone, for a total of 35 mice (Fig. 2). Two and 
5  weeks after injection, whole blood was collected from 
tail vein and correspondent serum was analysed with the 
Human Cytokine Array kit. At day 80, organs and tissues 
Fig. 1 Graphic representation of applications performed on CTCs cultivated for 14 days. The short-term cultivation provided CTCs available for 
cytometry evaluation of cell cycle phases distribution, immunofluorescence, protein extraction and cell-sorter protocols. Moreover, conditioned 
medium (aged 14 days) was collected and cellular production was analyzed
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were collected by scarified animals. Tissues were fro-
zen and then sectioned (8 μm thick) on slides for immu-
nofluorescence. Finally, the tissues were processed into 
cell suspensions for cytometric analysis. Tumor tissues 
excised from the 4 mice injected with 1  ×  104 tumour 
cells eCTCs-CD133posCK20posCD45neg were analyzed for 
CD133 expression by immunohistochemistry (CD133-
biotin Miltenyi Biotec) as previously described [14].
Statistical analysis
Data are shown as means ±  standard deviation (SD) of 
five blood samples (5  ml) collected from the patients. 
Statistical analyses and Kaplan Mayer curves were per-
formed using MedCalc software, version 12.3. Three way 
analysis of variance (ANOVA) was used to analyse the 
variation of the CK20 and Fibronectin expression associ-
ated with tumour’s stage and with the cultivation time (7 
and 14 days). Significance was set at p < 0.05.
Results and discussion
Collection and enrichment of CTCs
All patients were diagnosed with adenocarcinomas with 
moderately or poor differentiated histological grade. Five 
patients were in stages IV and III correspondent to stage 
(D) by Dukes classification. The correspondent mean 
value of the CTCs number investigated in whole blood 
was of 5  ±  1 cells/ml for CD133posCD45neg CTCs and 
29  ±  3 cells/ml for CK20posCD45neg CTCs. The mean 
value of the CTCs number investigated in whole blood 
of two patients in stage II correspondent to stage (A) by 
Dukes, was of 2 ±  1 cells/ml for CD133posCD45neg and 
1 ± 1 cells/ml for CK20posCD45neg CTCs. Further details 
about the clinicopathological features of the patients can 
be found in Table 1.
This phase of research is focused to prove that the most 
of CTCs are included in the working density phase at 
1.080 ÷ 1.090 (g/ml) [11]. Simulation experiment with a 
Fig. 2 Animal experiment design
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modified colon cancer cell line, GFP-HCT-116 cells, were 
performed. Cytometric analysis counted 88  ±  11  % of 
GFP-HCT-116 cells in the working density phase. More-
over, we investigated if the working density phase could 
be considered as the real CTCs enriched phase, also for 
colon cancer cells with epithelial to mesenchymal transi-
tion (EMT) phenotype. The presence of CTC expressing 
CK20, epithelial marker, and for fibronectin as mesen-
chymal markers, were evaluated, as reported in previous 
work [5]. Some reports suggest the migration of CTCs 
to the peripheral blood mononuclear cells layer during 
centrifugation [15]. The CTCs population was evaluated 
in both working density phase and mononuclear cells 
layer. The isolation of CK20 positive cells isolated from 
the mononuclear cell layer (red line) and from the work-
ing density phase (blue line) respectively, was resume 
in the Fig. 3 (central graphic). In particular, in advanced 
colon cancer (Dukes D stage), the percentage of cells 
positive for Fibronectin (up in the blue square of Fig. 3) 
was detected only in the working density phase (1.7 %). 
Conversely, CK20 positivity was detected in both mono-
nuclear cell layer (11  %; Fig.  3, down in the red square) 
and in working density phase (70 %; Fig. 3, down in the 
blue square). These results confirmed that the work-
ing density phase represent the CTCs-enriched phase in 
Ficoll-gradient.
The CTCs detected in the working density phase of 
affected patients in Dukes D stage was 11 ± 1 % for the 
expression of CD133posCD45neg CTCs and 89  ±  2  % 
for CK20posCD45neg CTCs, while in Dukes A stage was 
7 ± 1 % for CD133posCD45neg CTCs and of 3 ± 1 % for 
CK20posCD45neg CTCs.
CTCs in vitro expansion and characterization
Phenotypic characterization
When induced to grow in  vitro, tumor cells appeared as 
an adherent monolayer with or without sphere forma-
tion. The cultivation time was set at 14 days, after that the 
starting phenotypic configuration (analyzed just before 
CTCs seeding) changed in a percentage >35  %, as previ-
ously reported [11]. Non-adherent eCTCs were further 
expanded in suspension culture system to induce sphere 
formation. The spheres were analyzed for the expression of 
CD133, CK20 and CD45. The cancer cells forming spheres 
expressed CD133 (70 ± 8 %), CK20 (11 ± 9 %) and were 
CD45 negative. The characterization of eCTCs revealed 
that during their cultivation in  vitro their phenotype 
changes. The composition of eCTCs population is charac-
terized by different proportion of eCTCs subsets, according 
to the expression of epithelial antigens (CK20 or Epcam) or 
mesenchymal antigens as fibronectin (Fig. 4b). Three-way 
analysis of variance showed a significant difference for the 
expression of CK20 and fibronectin (p =  0.002) between 
two time-cultivation points (7 and 14 days in vitro). Moreo-
ver, the eCTCs phenotype showed significant difference in 
relation to tumour’s stage (Fig.  4b). Immunofluorescence 
analysis (Fig.  4c) showed the eCTCs phenotype express-
ing Epcam (green channel) and fibronectin (red channel); 
merged color image reported cellular elements character-
ized by the co-expression of fibronectin and epithelial anti-
gens highlighting EMT phenotypes. We concluded that 
eCTCs displaying EMT phenotype are detectable both in 
localized and advanced colon cancer cases, with a preva-
lence in the advanced cases.
Cell cycle analysis
Our method tests in vitro, through the short-time cultiva-
tion, the intrinsic property of cancer cells: their independ-
ent and anarchical proliferation. In order to evaluate the 
proliferation rate of CTCs, we applied the same procedure 
of CTCs isolation and cultivation on blood samples col-
lected by healthy volunteers, patients affected by chronic 
inflammation (ulcerative colitis and Crohn’s disease) and 
cancer colon patients. Twenty-nine subjects (14 males and 
15 females) with an age ranging from 25 to 77 years, were 
enrolled. The cell suspensions isolated from healthy blood 
samples, in correspondence of working density phase, 
contained epithelial cells not able to expand in  vitro. In 
Table 1 Characteristics of patients involved in the study
OS overall survival, DFS disease free survival
Patient’s characteristics
Patients Stage Grade Tumour site Sex Age OS (months) DFS (days)
P1 IV (D) Moderate Right colon M 73 10 90
P2 IV (D) Poor Para-colic F 66 11 75
P3 III (D) Moderate Sigmoid M 34 22 78
P4 II (A) Moderate Right colon M 58 35 180
P5 II (A) Moderate Right colon M 53 38 225
P6 IV (D) Moderate Sigmoid F 76 9 100
P7 IV (D) Poor Right colon M 65 11.5 97
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these adherent cells, the mean value of S-phase percent-
age was of 4.4 ± 2.3 %. Analogue adherent cells, with lim-
ited proliferation, were observed in subjects affected by 
chronic inflammation, and their S-phase was of 8 ± 5 %. 
Finally, the eCTCs isolated from samples of colon cancer 
patients were able to proliferate for at least two passages 
with a S-phase of 57 ± 20 %. The comparison of S-phase 
between healthy and inflammation versus colon cancer 
cases was statistically significant (p  <  0.001; Fig.  5). The 
experiment proved that it is possible to find circulating 
cells with an epithelial phenotype in subjects unaffected 
by cancer disease, so the count of CTCs can be not suf-
ficient to specifically define cancer condition. In fact, the 
sample of healthy cells isolated in vitro was unable to sur-
vive and expand while the sample of tumor cells was able 
to survive and expand as proved by S-phase percentage.
Cytokines array
Moreover, we analyzed the products released by the 
eCTCs derived from localized and advanced colon cancer 
cases. The corresponding amount of cytokines detected in 
conditioned medium are reported in Fig. 6a, c. The mem-
branes show a production of IL-6 and IL-8 cytokines with 
different concentration between the medium derived by 
localized and advanced colon cancer cases. Moreover, 
we focused our attention on the production of SDF-1 
(stromal cell-derived factor-1). The regulatory system 
SDF-1/CXCR4 (Chemokine (C-X-C motif ) receptor 4) 
is involved in the metastasis phase of colon, lung, and 
breast cancers [16–18]. CXCR4 is an antigen key regula-
tor of tumor invasiveness leading to local progression and 
tumor metastasis [19]. We found levels of SDF-1 in the 
conditioned medium by eCTCs of both localized 2/2 cases 
Fig. 3 CTCs collection and enrichment phase. The figure reports CK20 (down dot plots) and Fibronectin (up dot plots) expression (x-axis, logarithmic 
scale) on side scatter-height (SSC-H, y-axis, logarithmic scale) collected from two different gradient density phases corresponding to the mononu-
clear cell layer (red line) and CTC phase (blue line) respectively. Central histogram shows the overlay CK20 expression (x-axis, logarithmic scale) on 
CTCs (y-axis, percentage) of the two different density ranges
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with a mean value of pixel density of [(17 ±  20) ×  103] 
and advanced 5/5 cases with a mean value of pixel den-
sity of ((75 ± 20) × 103) cancer cases, as shown in Fig. 6a, 
c respectively. We concluded that SDF-1 is released by 
eCTCs derived from both localized and advanced colon 
cancer cases. Moreover, the evidence of the production 
ex vivo of SDF-1 was used as tool to monitor cancer cell 
survival in mice that during xenograft experiment did not 
develop macroscopic lesions. Clinical cases showing pri-
mary cultures of adherent eCTCs for localized (Fig.  6b) 
and advanced cases (Fig. 6d) were reported.
SCID xenografts
Characterization of injected circulating cancer cell
On the basis of SDF-1 production by eCTCs, CXCR4 
expression was investigated. The populations of eCTCs-
CXCR4pos were 9.0 ± 2.8 and 22.2 ± 5.4 % in localized 
and advanced cases, respectively. Moreover, adherent 
eCTCs were sorted for CXCR4 expression and two dif-
ferent populations were distinguished: eCTCs-CXCR4neg 
and eCTCs-CXCR4pos (Fig.  7a, b). eCTCs-CXCR4pos 
sorted after 14  days of cultivation were further ana-
lyzed for CK20 expression. The mean percentage of 
eCTCs-CXCR4posCK20posCD45neg was 77  ±  3  % in 
localized (Fig.  7a, right) and 81 ±  9  % in the advanced 
cases (Fig. 7b, right). We injected eCTCs-CXCR4posCK-
20posCD45neg in SCID mice (Fig.  7c, up). The group of 
mice injected with eCTCs-CXCR4posCK20posCD45neg 
segment did not develop macroscopic evidences of 
tumor lesions. In order to verify the success of trans-
plantation, we used SDF-1 released by eCTCs as guide-
line for monitoring cancer cells survival trend (Fig.  7c, 
down). The levels of SDF-1 were detectable in serum of 
the 80 % of mice injected, with a different concentration 
in localized and advanced cases (Fig.  7c, down). Con-
versely, SDF-1 was not detectable in mice injected with 
selected eCTCs-CXCR4negCK20negCD45neg segment, 
suggesting that these cells were unable to survive in vivo.
Finally, immunofluorescence analysis on mice tissues 
for the expression of CK20 confirmed the ability of 
the eCTCs-CXCR4posCK20pos segment to survive and 
disseminate in the mice, even if derived from local-
ized colon cancer patients. The histological sections 
Fig. 4 Phenotypic characterization of eCTCs. a Calpain expression was compared in the same patient between CTCs (collected before surgical 
treatment) and correspondent tumour tissue sample collected during surgical resection. Control α-tubulin immunoblot confirmed equal loading. 
b Bar graph displayed eCTCs dynamic phenotypic changes in different stage of tumour (according to Tumor-Node-Metastasis, UICC-2009) (data are 
presented as mean ± standard deviation). Multiple comparison procedures pairwise showed significant differences between advanced (T3N1M0, 
T4N1M1) versus localized colon cancer stages (T1N0M0, T2N0M0). *p < 0.05, **p ≤ 0.01. c–f, immunofluorescence characterization of eCTCs for 
epithelial (Epcam, green channel) and mesenchymal (Fibronectin, red channel) antigens expressions. Their co-expression on cell’s surface revealed 
the EMT phenotype (merged color image). Scale bars 50 μm
Fig. 5 Cell cycle analysis. The box plot compares S-phase percent-
age of adherent cells (isolated in correspondence to the working 
density phase and briefly expanded according to the protocol here 
reported for CTCs) isolated from healthy volunteers, patients affected 
by chronic inflammation (ulcerative colitis and Crohn’s disease) and 
colon cancer.**p < 0.001
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Fig. 6 Cytokines array and morphology of adherent eCTCs. Cytokines concentration was analysed in collected conditioned medium of eCTCs aged 
14 days. Histograms (a) and (c) show mean spot pixel density from the array membranes (red boxes) by localized and advanced cases, respectively 
(data are presented as mean ± standard deviation). In all conditioned medium, detectable levels of IL-6, IL-8, and SDF-1 cytokines were found. The 
histograms are representative of at least three independent experiments. The array membranes pictures show one representative case. Morphol-
ogy of eCTCs in adhesion isolated by localized (b) and advanced (d) cases is shown; in particular, brightfield image, phalloidin (green staining of 
cytoplasm), DAPI (blue staining of nuclei) and CK20 (red staining of positive cells). Scale bars 50 μm
(See figure on next page.) 
Fig. 7 Characterization of injected circulating cancer cells and survival trend. Representative dot plots show cell surface CXCR4 expression (x-axis) 
versus side scatter (SSC; y-axis) of pre-sorting (naive) and post-sort tumour cellular suspensions (a, b). After cell sorting the post-sorting cell popula-
tion was evaluated for the expression of CK20 reported in histograms (right panels) respectively in localized (a) and advanced (b) colon cancer. c 
Trends of SDF-1 (data are represented as mean ± standard deviation) in serum of mice injected with eCTCs-CXCR4posCKpos segment were reported. 
In mice injected with eCTCs-CXCR4posCKpos derived from localized colon case the levels of serum SDF-1 shows a sharp increase which peaking at 
days ninety (left panel). In mice injected with eCTCs-CXCR4posCKpos derived from advanced colon case the levels of serum SDF-1 show a steeper 
trend of the curve (right panel)
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of liver, brain, kidney and bone marrow mice show 
human eCTCs (derived from localized colon cancer 
cases) organized in microcolonies, without deep alter-
ation of tissue texture (Fig. 8). Conversely, the sections 
of mice livers treated with eCTCs-CXCR4posCK20pos 
(derived from advanced colon cancer cases), show an 
invasion of eCTCs, organized in clusters, subverting 
original tissue architecture. Moreover, the cytomet-
ric analysis of tissue suspension derived from mice 
liver show 27 ± 14 % CK20pos cells in localized and of 
Fig. 8 Xenograft developed with circulating tumor cells (eCTCs-CXCR4posCK20pos). Immunofluorescence analysis was performed using human 
monoclonal antibody direct against CK20 antigen. Images of liver derived from mice injected with eCTCs-CXCR4posCKpos segment isolated by local-
ized (Loc) and advanced (Adv) colon cases, are reported. Moreover, immunofluorescence analysis for kidney, brain and bone marrow (BM) collected 
from mice injected with eCTCs-CXCR4posCKpos segment derived from localized colon cancer case, is shown. Bright field image, DAPI (blue), CK20 
(red) and merge are shown. Scale bars 100 μm
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45 ± 20 % CK20pos cells in advanced cases (Additional 
file 1: Figure S3).
In conclusion, eCTCs-CXCR4posCK20pos segment, 
detectable in different proportion in localized and 
advanced cases, is able to survive and disseminate in tis-
sues other than their primary localization.
Characterization of injected circulating cancer stem cell
Non-adherent forming sphere, eCTCs-CD133posCK-
20posCD45neg, derived from localized and advanced colon 
cancer cases, were used to perform xenografts. Within 
2  weeks, the 100  % of mice presented macroscopic 
lesions on the right flank, in correspondence of site of 
CTCs injections (Additional file 1: Figure S4), confirming 
the intrinsic tumorigenic property of this eCTCs subset.
Overall, the experiments demonstrated that the 
eCTCs-CXCR4posCK20pos CTCs segment is not tumo-
rigenic but able to disseminate and survive in animal 
tissues. In the literature, the positivity for CXCR4 and 
CD133 was used in metastatic case to detect cancer stem 
cells (CSCs). The migration of invasive CSCs is primarily 
mediated by CXCR4/SDF-1 axis gradient, able to attract 
tumor cells regulating them for proliferation and inva-
sion [20, 21]. Consequently, on the basis of our results, 
in early colon cancer cases it is possible to detect CTCs 
expressing CXCR4. This CTCs subset correlated with a 
dissemination potential. Moreover, the CTCs expressing 
CD133, like the CSCs, represent the subset with tumori-
genic power. Our in vitro and in vivo characterization of 
eCTCs expressing CD133 revealed that their plasticity is 
a dynamic property increasing with the stage of the dis-
ease [22].
Benchmarking clinical data and metastatic risk assessment
The observation of the patients’ outcomes was conducted 
for 3 years on a limited panel of seven patients. The small 
number of patients enrolled in this study have not statisti-
cal significance, but the trend curves resulting suggestive. 
In particular, the arithmetic mean of the expression value 
for CD133 and CK20 of CTCs was used as cut-off to strat-
ify the patients. The curve of overall survival (OS) shows 
an adverse prognosis for the patients with high CD133pos-
CTCs. These cells are also tumorigenic in the mice model. 
In terms of disease free (DF), the patient with high per-
centage of CTCs expressing CK20 have adverse prognosis 
(Fig. 9). This subset corresponds to the pool of eCTCs able 
to survive and disseminate in the mice model. Tumor tis-
sue remodelling during cancer progression unbalances the 
proportion of all cancer cells subpopulations, as reflected 
in the heterogeneous composition of circulating progeny. 
To better monitor the patient clinical course it should be 
necessary to know the different subsets of cancer cells and 
their dynamic changes. Our study highlights that tumo-
rigenic subset (CD133pos) represents the predominant 
Fig. 9 Benchmarking clinical data. In a the box of CD133 and in b CK20 positivity distribution applying Kolmogorov–Smirnov test. Correspondent 
arithmetic means for each variable was used as cut-off value to stratify the patients according to low (a box) and high (d box) expression for CD133 
and CK20 antigens, respectively. Moreover, arithmetic means for each variable was used as cut-off value to distinguish two subgroups of patients. In 
function of the low and high expression for each antigen the relative overall survival (c) and disease free (d) were calculated
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subtype of CTCs in the last phase of tumour progression. 
On the other hand, the non-tumorigenic circulating prog-
eny (CK20pos), prevalently detected in the localized phase 
of disease, is able to disseminate.
Despite the low sample size, these results suggest 
that the high presence of non-tumorigenic CTCs sub-
set can negatively influence the disease free survival, 
probably promoting relapses in the tissue were they are 
disseminated.
Conclusion
Detailing CTCs in distinct subsets, defined by qualitative/
quantitative measurement, might be useful to stratify the 
patients according to a personalized metastatic risk score. 
The “emo-cytometric” approach on CTCs here described 
can be considered an interesting tool to improve the clini-
cal surveillance and reducing the clinical cost.
Additional file
Additional file 1: Figure S1. Sensibility, specificity and purity of CTCs 
detection methodology. The sensitivity of the methodology was calcu-
lated through the formula employing mean values (expressed in percent-
age) for each CTCs subsets identified by the combined expression of CK20 
and CD45, found in the total cellular suspension collected from the work-
ing density phase. The sensitivity or the capability to detect the real subset 
of CTCs CK20pos corresponded to 91 %. The specificity, corresponding to 
the probability of a negative test, was calculated at about 87 %. Finally, the 
purity was at 75 %. Figure S2. Resolution of CTCs detection methodol-
ogy. To verify that the collected fraction was enriched in cancer cells, HCT 
116 cells were infected with pAdenoVator-CMV-IRES-GFP reporter. Human 
cancer colon cell lines HCT 116 were cultured in RPMI1640 medium 
containing 10 % fetal bovine serum (FBS), 2 mmol/l L-glutamine, and 
30 mg penicillin G/0.05 g streptomycin. Cells were plated at 8 x 106 per 
well onto a six-well plate 24 hours before infection, and were infected 
with adenoviral vector. In order to perform infections, HCT 116 cells were 
incubated with pAdenoVator-CMV5(CuO)-IRES-GFP (Qbiogene, Carlsbad, 
CA) in serum free medium for 1 hour at 37 °C. Both vectors were used at 
multiplicity of infection (m.o.i.) of 3000 physical particles/cell, experimen-
tally determined as the lowest m.o.i. at which the majority of the cell 
population is infected (as assessed by EGFP expression). Twenty-four hours 
later, both adherent and floating cells were harvested, washed in PBS and 
counted. Different concentration of HCT 116-GFP (HCT 116*) were put 
in entire blood sample (5 ml) and were evaluated through cytometric 
analysis. The resolution for the minimal concentration of HCT 116* (8 x 
103 cell/5 ml) put in a volume of peripheral blood sample of 5ml, useful to 
detect them in the working density phase, was calculated at 5,8 cells/5 ml 
(B). Figure S3. DTCs in livers of mice treated with localized and advanced 
cancer eCTCs. Dot Plots report the expression of CK20 antigen on human 
colon cancer cells disseminated within liver tissue of mouse submit-
ted to xenograft procedure. In particular, dot plot in (A) shows human 
colon cancer cell CK20 positive founded in liver tissue of mouse injected 
with eCTCs-CXCR4negCKneg referred as control. Dot plots in (B) and (C) 
show human cancer colon cells expressing CK20 marker in liver tissues 
of mouse injected with eCTCs-CXCR4posCKpos derived from localized (B) 
and advanced (C) colon cancer cases respectively. Figure S4. xenograft 
developed with circulating stem cells. Xenograft procedure developed 
injecting eCTCs-CD45negCD133pos organized in spheres (A). In (B) immu-
nofluorescence positive for CD133 (green staining). In (C) Tumour forma-
tions produced within 2 weeks and after 80 days. Immunohistochemical 
analysis shows the distribution of the cancer colon cells expressing CD133 
(brown staining) in the tumour sections of 8 μm (D).
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